Sheet

	Complete if Known		
Substitute for form 1449A/B/PTO	Application Number	10/588,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing / 371(c) Date	February 16, 2007	
	First Named Inventor	MAGILAVY	
	Group Art Unit	1644	
	Evaminer Name	Phillip Gambel	

Attorney Docket Number

253780

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	C624	JEFFERIS et al., IgG-Fo-medicated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation, <i>Immunological Reviews</i> 1998, 163: 59-76 (June 1998)	
	C625	JANEWAY et al., Immunobiology, The immune system in health and disease, Third Edition, Current Biology Ltd./Garland Publishing Inc., New York, pp. 7:4-7:7 (1997)	

Examiner digitature	/Frillip Gallibel/	Date Considered	04/02/2009	
* If the reference is not in			ation in whole or in part or (b) a concise statement	

of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign pather office in a counterport foreign and included the degree of relevance found by the foreign office and the counterport of the counte